AAPL   321.12 (-0.23%)
MSFT   182.42 (-0.22%)
FB   228.34 (-1.54%)
GOOGL   1,430.28 (-0.32%)
AMZN   2,461.23 (-0.40%)
NVDA   350.76 (-0.42%)
CGC   16.32 (-0.97%)
BABA   210.41 (+1.86%)
MU   46.44 (+0.22%)
GE   6.94 (+2.66%)
TSLA   892.21 (-0.66%)
AMD   53.09 (-1.01%)
T   31.06 (+0.42%)
ACB   14.17 (+0.50%)
F   5.95 (+1.36%)
GILD   74.43 (-0.97%)
DIS   118.89 (+0.10%)
NFLX   424.28 (-0.39%)
BAC   25.33 (+2.93%)
BA   155.38 (+2.64%)
AAPL   321.12 (-0.23%)
MSFT   182.42 (-0.22%)
FB   228.34 (-1.54%)
GOOGL   1,430.28 (-0.32%)
AMZN   2,461.23 (-0.40%)
NVDA   350.76 (-0.42%)
CGC   16.32 (-0.97%)
BABA   210.41 (+1.86%)
MU   46.44 (+0.22%)
GE   6.94 (+2.66%)
TSLA   892.21 (-0.66%)
AMD   53.09 (-1.01%)
T   31.06 (+0.42%)
ACB   14.17 (+0.50%)
F   5.95 (+1.36%)
GILD   74.43 (-0.97%)
DIS   118.89 (+0.10%)
NFLX   424.28 (-0.39%)
BAC   25.33 (+2.93%)
BA   155.38 (+2.64%)
AAPL   321.12 (-0.23%)
MSFT   182.42 (-0.22%)
FB   228.34 (-1.54%)
GOOGL   1,430.28 (-0.32%)
AMZN   2,461.23 (-0.40%)
NVDA   350.76 (-0.42%)
CGC   16.32 (-0.97%)
BABA   210.41 (+1.86%)
MU   46.44 (+0.22%)
GE   6.94 (+2.66%)
TSLA   892.21 (-0.66%)
AMD   53.09 (-1.01%)
T   31.06 (+0.42%)
ACB   14.17 (+0.50%)
F   5.95 (+1.36%)
GILD   74.43 (-0.97%)
DIS   118.89 (+0.10%)
NFLX   424.28 (-0.39%)
BAC   25.33 (+2.93%)
BA   155.38 (+2.64%)
AAPL   321.12 (-0.23%)
MSFT   182.42 (-0.22%)
FB   228.34 (-1.54%)
GOOGL   1,430.28 (-0.32%)
AMZN   2,461.23 (-0.40%)
NVDA   350.76 (-0.42%)
CGC   16.32 (-0.97%)
BABA   210.41 (+1.86%)
MU   46.44 (+0.22%)
GE   6.94 (+2.66%)
TSLA   892.21 (-0.66%)
AMD   53.09 (-1.01%)
T   31.06 (+0.42%)
ACB   14.17 (+0.50%)
F   5.95 (+1.36%)
GILD   74.43 (-0.97%)
DIS   118.89 (+0.10%)
NFLX   424.28 (-0.39%)
BAC   25.33 (+2.93%)
BA   155.38 (+2.64%)
Log in

NASDAQ:ARVNArvinas Stock Price, Forecast & News

$32.06
-1.16 (-3.49 %)
(As of 06/2/2020 10:06 AM ET)
Add
Compare
Today's Range
$31.93
Now: $32.06
$33.80
50-Day Range
$33.27
MA: $48.42
$56.74
52-Week Range
$15.19
Now: $32.06
$61.57
Volume1,813 shs
Average Volume883,221 shs
Market Capitalization$1.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.87
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARVN
CUSIPN/A
CIKN/A
Phone203-535-1456

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.98 million
Book Value$6.72 per share

Profitability

Net Income$-70,290,000.00
Net Margins-171.74%

Miscellaneous

Employees83
Market Cap$1.26 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableNot Optionable

Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.

Arvinas (NASDAQ:ARVN) Frequently Asked Questions

How has Arvinas' stock been impacted by COVID-19 (Coronavirus)?

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ARVN stock has decreased by 26.7% and is now trading at $32.28. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Arvinas?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arvinas.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Arvinas.

How were Arvinas' earnings last quarter?

Arvinas Inc (NASDAQ:ARVN) posted its earnings results on Tuesday, April, 28th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.57) by $0.01. The company had revenue of $6.24 million for the quarter, compared to the consensus estimate of $5.18 million. Arvinas had a negative net margin of 171.74% and a negative return on equity of 30.74%. View Arvinas' earnings history.

What price target have analysts set for ARVN?

11 brokerages have issued 1 year price objectives for Arvinas' shares. Their forecasts range from $38.00 to $75.00. On average, they anticipate Arvinas' share price to reach $57.10 in the next twelve months. This suggests a possible upside of 76.9% from the stock's current price. View analysts' price targets for Arvinas.

Has Arvinas been receiving favorable news coverage?

Media coverage about ARVN stock has been trending very positive recently, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arvinas earned a coverage optimism score of 3.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutArvinas.

Are investors shorting Arvinas?

Arvinas saw a drop in short interest in May. As of May 15th, there was short interest totaling 2,570,000 shares, a drop of 11.4% from the April 30th total of 2,900,000 shares. Based on an average trading volume of 401,000 shares, the days-to-cover ratio is currently 6.4 days. Currently, 10.1% of the company's stock are short sold. View Arvinas' Current Options Chain.

Who are some of Arvinas' key competitors?

What other stocks do shareholders of Arvinas own?

Who are Arvinas' key executives?

Arvinas' management team includes the following people:
  • Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 59)
  • Mr. Sean A. Cassidy, CFO & Treasurer (Age 49)
  • Dr. Ian Taylor, Chief Scientific Officer (Age 56)
  • Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
  • Dr. Andrew Crew, Chief Technology Officer (Age 54)

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.56%), 5AM Venture Management LLC (2.55%), Orbimed Advisors LLC (2.54%), State Street Corp (1.21%), ArrowMark Colorado Holdings LLC (0.97%) and Rock Springs Capital Management LP (0.73%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, John G Houston, Liam Ratcliffe, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am. View institutional ownership trends for Arvinas.

Which major investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, 5AM Venture Management LLC, Ghost Tree Capital LLC, Pictet Asset Management Ltd., Spark Investment Management LLC, Citigroup Inc., Sphera Funds Management LTD., and UBS Group AG. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Sean A Cassidy, and Ventures Iii LP 5Am. View insider buying and selling activity for Arvinas.

Which major investors are buying Arvinas stock?

ARVN stock was acquired by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Federated Hermes Inc., Two Sigma Advisers LP, AQR Capital Management LLC, Rock Springs Capital Management LP, State Street Corp, Schroder Investment Management Group, and Castleark Management LLC. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, and Timothy M Shannon. View insider buying and selling activity for Arvinas.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $32.28.

How big of a company is Arvinas?

Arvinas has a market capitalization of $1.26 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.